Sign in

Private company

Talis Biomedical Corp

Talis Biomedical Corp is an American laboratory analytical instruments company, incorporated in Delaware.1 It is headquartered in Chicago, Illinois.1

Last updated Oct 21, 2026.

Overview

  • IndustryLaboratory Analytical Instruments1
  • HeadquartersChicago, Illinois1
  • Incorporated inDE2
  • Business address1375 West Fulton Market, Suite 700, Chicago, Il 606072
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

All references to “Talis Biomedical,” “Talis,” “the Company,” “we,” “our,” and “us” in this Annual Report refer to Talis Biomedical Corporation.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-3131.0%Operating margin4
-2905.7%Net margin4
-55.7%Revenue growth, 20234
-89.7%Return on equity4
-$53.7MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue0¢$41.0K
  • Research and development59¢$40.7M
  • Selling, general and admin41¢$28.2M

Out of $2.1M in revenue.4 The company lost money this year.

Financial statements

Revenue54$2.1M in 2023−74% since 2021
0$2.5M$5.0M$7.5M$10.0M2021: $8.2M$8.2M20212022: $4.8M$4.8M2022−41%2023: $2.1M$2.1M2023−56%
Operating income654-$66.8M in 2023−27% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$91.2M-$91.2M20202021: -$191.8M-$191.8M2021+110%2022: -$115.1M-$115.1M2022−40%2023: -$66.8M-$66.8M2023−42%
Net income654-$62.0M in 2023−32% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$91.1M-$91.1M20202021: -$192.0M-$192.0M2021+111%2022: -$113.0M-$113.0M2022−41%2023: -$62.0M-$62.0M2023−45%
Fiscal year20192020202120222023
Revenue$8.2M5$4.8M4$2.1M4
Cost of revenue$05$8.4M4$41.0K4
Research and development$89.0M6$157.6M5$70.8M4$40.7M4
Selling, general and admin$13.1M6$42.4M5$40.7M4$28.2M4
Operating expenses$200.0M6$120.0M4$68.9M4
Operating income-$91.2M6-$191.8M5-$115.1M4-$66.8M4
Income tax$06$05$04$04
Net income-$91.1M6-$192.0M5-$113.0M4-$62.0M4
Earnings per share-$8.485-$62.774-$34.124
Earnings per share (diluted)-$8.485-$62.774-$34.124
Shares (weighted, basic)22.7M shares51.8M shares41.8M shares4
Shares (weighted, diluted)22.7M shares51.8M shares41.8M shares4

Compare Talis Biomedical Corp with another company

Corporate structure

Talis Biomedical Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Talis Biomedical Corp

  • Talis Biomedical Corp Chicago, Illinois

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Talis Biomedical Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$04 Dec 31, 2023$984.0K4 Dec 31, 2022−100.0%
Property and equipment, before depreciation$16.0M4 Dec 31, 2023$15.2M4 Dec 31, 2022+5.4%
Accumulated depreciation$12.9M4 Dec 31, 2023$12.8M4 Dec 31, 2022+1.0%
Property and equipment, net$3.0M4 Dec 31, 2023$3.3M4 Dec 31, 2022−8.5%
Operating-lease assets (leased space)$12.4M4 Dec 31, 2023$30.9M4 Dec 31, 2022−59.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$76.7M4 Dec 31, 2023$130.2M4 Dec 31, 2022−41.1%

Leadership

Who has led Talis Biomedical Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Brian Coe2021
  2. Kimberly J. Popovits2021
  3. Brian J. Blaser2021

President

  1. Brian J. Blaser2021
  2. Andrew A. Lukowiak2023

Chief financial officer

  1. Rebecca Markovich2023

Chief operating officer

  1. Douglas Liu2021
2025
Board members and other officers (17)

Former names

  • SlipChip CorpAug 20, 2013 to Oct 17, 20172

Timeline

  1. Sep 17, 20248-K Entered a material agreement28
  2. Sep 6, 20248-K Entered a material agreement29
  3. Sep 5, 20248-K Entered a material agreement30
  4. Sep 3, 20248-K Entered a material agreement31
  5. Aug 23, 20248-K Listing notice or transfer32
  6. Aug 6, 20248-K Executive or director change33
  7. Jun 25, 20248-K Entered a material agreement34
  8. Jun 3, 20248-K Entered a material agreement35
  9. May 3, 20248-K Entered a material agreement36
  10. Apr 11, 20248-K Executive or director change37
  11. Jan 26, 20248-K Executive or director change38
  12. Nov 14, 20238-K Results of operations39
  13. Dec 2, 2021New chief executive Brian J. Blaser becomes CEO11
  14. Aug 31, 2021New chief executive Kimberly J. Popovits becomes CEO10
  15. Feb 11, 2021New chief executive Brian Coe becomes CEO9

Calendar

When it reported results

  1. Nov 14, 2023Reported quarterly or annual results39
  2. Aug 10, 2023Reported quarterly or annual results40
  3. May 11, 2023Reported quarterly or annual results41
  4. Mar 22, 2023Reported quarterly or annual results42
  5. Nov 3, 2022Reported quarterly or annual results43
  6. Aug 2, 2022Reported quarterly or annual results44
  7. May 10, 2022Reported quarterly or annual results45
  8. Mar 15, 2022Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

123 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 37 major events, 38 insider forms, 12 large holders, 24 other. The latest 20:

  1. Oct 10, 2024SC 13D/A EDGAR
  2. Sep 30, 202415-12G EDGAR
  3. Sep 17, 20248-K EDGAR
  4. Sep 9, 20244 EDGAR
  5. Sep 9, 2024S-8 POS EDGAR
  6. Sep 9, 2024S-8 POS EDGAR
  7. Sep 9, 2024S-8 POS EDGAR
  8. Sep 9, 2024S-8 POS EDGAR
  9. Sep 6, 20248-K EDGAR
  10. Sep 5, 20244 EDGAR
  11. Sep 5, 20248-K/A EDGAR
  12. Sep 4, 20244 EDGAR
  13. Sep 3, 20248-K EDGAR
  14. Aug 28, 20244 EDGAR
  15. Aug 23, 20248-K EDGAR
  16. Aug 19, 202410-Q EDGAR
  17. Aug 14, 2024SC 13G/A EDGAR
  18. Aug 14, 20243 EDGAR
  19. Aug 14, 2024SC 13G EDGAR
  20. Aug 14, 2024NT 10-Q EDGAR

The 123 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 6, 2024Leonard Braden Michael10% ownerBuy25,000$1.48$37.0KForm 4
Sep 5, 2024Leonard Braden Michael10% ownerBuy5,100$1.40$7.1KForm 4
Sep 3, 2024Leonard Braden Michael10% ownerBuy500$4.00$2.0KForm 4
Aug 30, 2024Leonard Braden Michael10% ownerBuy151$4.25$642Form 4
Aug 28, 2024Leonard Braden Michael10% ownerBuy1,215$3.96$4.8KForm 4
Aug 26, 2024Leonard Braden Michael10% ownerBuy13,167$3.90$51.4KForm 4
Nov 18, 2021BAKER BROS. ADVISORS LPDirectorBuy50,000$4.37$218.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Talis Biomedical Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTalis Biomedical Corp1
  • CIK0001584751
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3826 Laboratory Analytical Instruments1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1375 West Fulton Market, Suite 700, Chicago, IL 606071
  • Phone650-433-30001
  • Shares outstanding31,686,494 as of Aug 14, 20248
  • Public float$8.2B as of Jun 30, 20234
  • On EDGAR sinceAug 20, 20131
  • Filings188 in all: 4 (43), 8-K (42), 3 (22), 10-Q (11), SC 13G/A (8), CORRESP (5), 10-K (4), S-8 (4)1
    All 36 form types

    S-8 POS (4), SC 13D/A (4), SC 13G (4), UPLOAD (4), D (3), EFFECT (3), DEF 14A (2), DEFA14A (2), NT 10-Q (2), S-1/A (2), S-3 (2), 15-12G (1), 25-NSE (1), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), PRE 14A (1), RW (1), S-1 (1), S-1MEF (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2024
    Quarterly report (10-Q) Aug 19, 2024
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Sep 17, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51